4//SEC Filing
Haqq Christopher 4
Accession 0001209191-19-008526
CIK 0001604464other
Filed
Feb 7, 7:00 PM ET
Accepted
Feb 8, 4:28 PM ET
Size
14.8 KB
Accession
0001209191-19-008526
Insider Transaction Report
Form 4
Haqq Christopher
Chief Medical Officer
Transactions
- Sale
Common Stock
2019-02-06$38.78/sh−9,698$376,088→ 273,205 total - Sale
Common Stock
2019-02-06$38.04/sh−2,677$101,833→ 282,903 total - Tax Payment
Common Stock
2019-02-06$38.47/sh−1,512$58,167→ 271,693 total - Award
Common Stock
2019-02-06+15,000→ 286,693 total - Award
Employee Stock Option (Right to Buy)
2019-02-06+30,000→ 30,000 totalExercise: $38.47Exp: 2029-02-05→ Common Stock (30,000 underlying)
Holdings
- 17,312(indirect: See footnote)
Common Stock
- 2,688(indirect: See footnote)
Common Stock
Footnotes (8)
- [F1]Transaction pursuant to Rule 10b5-1 Plan adopted January 25, 2018.
- [F2]The price in Column 4 is a weighted average sale price. The prices actually received ranged from $37.61 to $38.54. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- [F3]The price in Column 4 is a weighted average sale price. The prices actually received ranged from $38.67 to $38.89. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- [F4]Shares withheld to cover tax obligation from settlement of vested restricted stock units.
- [F5]These restricted stock units vest in four equal annual installments on each of the first, second, third and fourth anniversaries of the grant date, subject to the reporting person's continuous service.
- [F6]The shares are held by the Chris Haqq 2014 GRAT, of which the Reporting Person is trustee.
- [F7]The shares are held by The Havenside Trust, of which the Reporting Person is trustee.
- [F8]1/48th of the shares subject to the stock option vest and become exercisable each month following February 6, 2019, subject to the reporting person's continuous service.
Documents
Issuer
Atara Biotherapeutics, Inc.
CIK 0001604464
Entity typeother
Related Parties
1- filerCIK 0001612095
Filing Metadata
- Form type
- 4
- Filed
- Feb 7, 7:00 PM ET
- Accepted
- Feb 8, 4:28 PM ET
- Size
- 14.8 KB